Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

patient expectations

- PMLiVE

Sarepta bounces back with new gene therapy data

Announces positive results in treatment of limb-girdle muscular dystrophy

- PMLiVE

UK immunology biotech MiroBio launches with $34m fundraising

Will develop therapeutic antibodies for autoimmune diseases

- PMLiVE

How technology is driving new trends in patient engagement

by Alicia Staley

- PMLiVE

Gilead builds case for Descovy PrEP after FDA approval

Reported statistically significant improvements in kidney function

- PMLiVE

J&J pledges $500m investment into HIV and tuberculosis R&D

Aims to help eliminate both diseases by 2030

- PMLiVE

Understanding the patient journey

What we can learn from customer service

- PMLiVE

J&J bags FDA breakthrough designation for prostate cancer drug

Could challenge rival PARP inhibitor Lynparza

- PMLiVE

Aspen to pay millions to NHS following drug pricing investigation

CMA found company colluded to create a monopoly in UK market

- PMLiVE

Gilead claims FDA okay for Descovy as second PrEP option

Can now push new indication before generics dent franchise

- PMLiVE

Arbutus hit hard as new hep B drug fails on safety

Shares have fallen sharply since company reported results

#LucidLife is just about to get better with the move to Middlesex House

With only a few weeks to go Jan Steele, Lucid co-founder and COO discusses how the move to Middlesex House supports its commitment to making Lucid a great place to...

Lucid Group Communications Limited

- PMLiVE

Sarepta rival NS Pharma files Duchenne drug with FDA

Another blow for Sarepta following FDA rejection earlier this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links